Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy.

Journal Information

Full Title: J Mater Chem B

Abbreviation: J Mater Chem B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Nanotechnology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest Dr Ishihara is a co-founder and shareholder of ArrowImmune Inc., which develops anti-cancer immunotherapies. The other authors declare no conflicts of interest."

Evidence found in paper:

"This work was in part supported by Imperial College London's internal funding (to J. I.). We thank Cancer Research UK (to J. I.) and the Academy of Medical Sciences (to J. I.). K. S. was supported by JSPS Overseas Research Fellowships (202160429). Fig. 1, 6, 9 and 11 were made with BioRender.com."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025